Cargando…

Discovery and Characterization of a Novel Series of Chloropyrimidines as Covalent Inhibitors of the Kinase MSK1

[Image: see text] We describe the identification and characterization of a series of covalent inhibitors of the C-terminal kinase domain (CTKD) of MSK1. The initial hit was identified via a high-throughput screening and represents a rare example of a covalent inhibitor which acts via an S(N)Ar react...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, Adrian, Abendroth, Jan, Bolejack, Madison J., Ceska, Tom, Dell’Aiera, Sylvie, Ellis, Victoria, Fox, David, François, Cyril, Muruthi, Muigai M., Prével, Camille, Poullennec, Karine, Romanov, Sergei, Valade, Anne, Vanbellinghen, Alain, Yano, Jason, Geraerts, Martine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290008/
https://www.ncbi.nlm.nih.gov/pubmed/35859861
http://dx.doi.org/10.1021/acsmedchemlett.2c00134
_version_ 1784748789995667456
author Hall, Adrian
Abendroth, Jan
Bolejack, Madison J.
Ceska, Tom
Dell’Aiera, Sylvie
Ellis, Victoria
Fox, David
François, Cyril
Muruthi, Muigai M.
Prével, Camille
Poullennec, Karine
Romanov, Sergei
Valade, Anne
Vanbellinghen, Alain
Yano, Jason
Geraerts, Martine
author_facet Hall, Adrian
Abendroth, Jan
Bolejack, Madison J.
Ceska, Tom
Dell’Aiera, Sylvie
Ellis, Victoria
Fox, David
François, Cyril
Muruthi, Muigai M.
Prével, Camille
Poullennec, Karine
Romanov, Sergei
Valade, Anne
Vanbellinghen, Alain
Yano, Jason
Geraerts, Martine
author_sort Hall, Adrian
collection PubMed
description [Image: see text] We describe the identification and characterization of a series of covalent inhibitors of the C-terminal kinase domain (CTKD) of MSK1. The initial hit was identified via a high-throughput screening and represents a rare example of a covalent inhibitor which acts via an S(N)Ar reaction of a 2,5-dichloropyrimidine with a cysteine residue (Cys440). The covalent mechanism of action was supported by in vitro biochemical experiments and was confirmed by mass spectrometry. Ultimately, the displacement of the 2-chloro moiety was confirmed by crystallization of an inhibitor with the CTKD. We also disclose the crystal structures of three compounds from this series bound to the CTKD of MSK1, in addition to the crystal structures of two unrelated RSK2 covalent inhibitors bound to the CTKD of MSK1.
format Online
Article
Text
id pubmed-9290008
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-92900082022-07-19 Discovery and Characterization of a Novel Series of Chloropyrimidines as Covalent Inhibitors of the Kinase MSK1 Hall, Adrian Abendroth, Jan Bolejack, Madison J. Ceska, Tom Dell’Aiera, Sylvie Ellis, Victoria Fox, David François, Cyril Muruthi, Muigai M. Prével, Camille Poullennec, Karine Romanov, Sergei Valade, Anne Vanbellinghen, Alain Yano, Jason Geraerts, Martine ACS Med Chem Lett [Image: see text] We describe the identification and characterization of a series of covalent inhibitors of the C-terminal kinase domain (CTKD) of MSK1. The initial hit was identified via a high-throughput screening and represents a rare example of a covalent inhibitor which acts via an S(N)Ar reaction of a 2,5-dichloropyrimidine with a cysteine residue (Cys440). The covalent mechanism of action was supported by in vitro biochemical experiments and was confirmed by mass spectrometry. Ultimately, the displacement of the 2-chloro moiety was confirmed by crystallization of an inhibitor with the CTKD. We also disclose the crystal structures of three compounds from this series bound to the CTKD of MSK1, in addition to the crystal structures of two unrelated RSK2 covalent inhibitors bound to the CTKD of MSK1. American Chemical Society 2022-06-25 /pmc/articles/PMC9290008/ /pubmed/35859861 http://dx.doi.org/10.1021/acsmedchemlett.2c00134 Text en © 2022 American Chemical Society https://pubs.acs.org/page/policy/termsofuse.htmlMade available for a limited time for personal research and study only License (https://pubs.acs.org/page/policy/termsofuse.html) .
spellingShingle Hall, Adrian
Abendroth, Jan
Bolejack, Madison J.
Ceska, Tom
Dell’Aiera, Sylvie
Ellis, Victoria
Fox, David
François, Cyril
Muruthi, Muigai M.
Prével, Camille
Poullennec, Karine
Romanov, Sergei
Valade, Anne
Vanbellinghen, Alain
Yano, Jason
Geraerts, Martine
Discovery and Characterization of a Novel Series of Chloropyrimidines as Covalent Inhibitors of the Kinase MSK1
title Discovery and Characterization of a Novel Series of Chloropyrimidines as Covalent Inhibitors of the Kinase MSK1
title_full Discovery and Characterization of a Novel Series of Chloropyrimidines as Covalent Inhibitors of the Kinase MSK1
title_fullStr Discovery and Characterization of a Novel Series of Chloropyrimidines as Covalent Inhibitors of the Kinase MSK1
title_full_unstemmed Discovery and Characterization of a Novel Series of Chloropyrimidines as Covalent Inhibitors of the Kinase MSK1
title_short Discovery and Characterization of a Novel Series of Chloropyrimidines as Covalent Inhibitors of the Kinase MSK1
title_sort discovery and characterization of a novel series of chloropyrimidines as covalent inhibitors of the kinase msk1
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290008/
https://www.ncbi.nlm.nih.gov/pubmed/35859861
http://dx.doi.org/10.1021/acsmedchemlett.2c00134
work_keys_str_mv AT halladrian discoveryandcharacterizationofanovelseriesofchloropyrimidinesascovalentinhibitorsofthekinasemsk1
AT abendrothjan discoveryandcharacterizationofanovelseriesofchloropyrimidinesascovalentinhibitorsofthekinasemsk1
AT bolejackmadisonj discoveryandcharacterizationofanovelseriesofchloropyrimidinesascovalentinhibitorsofthekinasemsk1
AT ceskatom discoveryandcharacterizationofanovelseriesofchloropyrimidinesascovalentinhibitorsofthekinasemsk1
AT dellaierasylvie discoveryandcharacterizationofanovelseriesofchloropyrimidinesascovalentinhibitorsofthekinasemsk1
AT ellisvictoria discoveryandcharacterizationofanovelseriesofchloropyrimidinesascovalentinhibitorsofthekinasemsk1
AT foxdavid discoveryandcharacterizationofanovelseriesofchloropyrimidinesascovalentinhibitorsofthekinasemsk1
AT francoiscyril discoveryandcharacterizationofanovelseriesofchloropyrimidinesascovalentinhibitorsofthekinasemsk1
AT muruthimuigaim discoveryandcharacterizationofanovelseriesofchloropyrimidinesascovalentinhibitorsofthekinasemsk1
AT prevelcamille discoveryandcharacterizationofanovelseriesofchloropyrimidinesascovalentinhibitorsofthekinasemsk1
AT poullenneckarine discoveryandcharacterizationofanovelseriesofchloropyrimidinesascovalentinhibitorsofthekinasemsk1
AT romanovsergei discoveryandcharacterizationofanovelseriesofchloropyrimidinesascovalentinhibitorsofthekinasemsk1
AT valadeanne discoveryandcharacterizationofanovelseriesofchloropyrimidinesascovalentinhibitorsofthekinasemsk1
AT vanbellinghenalain discoveryandcharacterizationofanovelseriesofchloropyrimidinesascovalentinhibitorsofthekinasemsk1
AT yanojason discoveryandcharacterizationofanovelseriesofchloropyrimidinesascovalentinhibitorsofthekinasemsk1
AT geraertsmartine discoveryandcharacterizationofanovelseriesofchloropyrimidinesascovalentinhibitorsofthekinasemsk1